A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
Latest Information Update: 17 Dec 2025
At a glance
- Drugs Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms DAN-COVID
Most Recent Events
- 17 Dec 2025 New trial record